A US Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and...
Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.
Future of promising Alzheimer’s treatment Leqembi could depend on access to data reporting, analysis:...
By
Aaron Dorman
Feb 16, 2024
Organizations must have clearer guidelines as to how data on lecanemab will be collected, pooled and studied, policy experts say.
One in seven drug supply chain issue reports tied to drug shortages
Apr 10, 2024
Supply disruptions increased for drugs with and without reports at the start of the COVID-19 pandemic.
Nirmatrelvir-ritonavir does not speed up alleviation of COVID-19 symptoms
Apr 05, 2024
The time to sustained alleviation of COVID-19 symptoms was not significantly shorter with nirmatrelvir-ritonavir versus placebo.
Risk profile IDs COVID-19 patients who will benefit from baricitinib
Feb 26, 2024
Baricitinib plus remdesivir was linked to a reduced risk of death and progression to invasive mechanical ventilation.